Tamoxifen: The Most Widely Used Drug in Breast Cancer Treatment

Tamoxifenis a selective estrogen receptor modulator (SERM) that has been central to breast cancer treatment algorithms for approximately half a century. Particularly in estrogen receptor (ER) -positive tumors, it significantly reduces recurrence risk, extends disease-free survival and can be used in both premenopausal and postmenopausal patients. Preclinical and clinical data show that tamoxifen has an antiestrogenic effect in breast tissue while displaying partial agonist effects in certain other tissues, such as the endometrium and bone. This tissue-selective profile determines both drug effectiveness and its range of side effects.

Current guidelines recommend it in early-stage hormone-positive disease for adjuvant (preventive) purposes for at least 5 years, extended to 7–10 years according to risk, tolerance and menopausal status. In metastatic (stage 4) and inoperable cases, it is used for palliative purposes to control symptoms and extend survival. 

Mechanism of Action

Tamoxifen is designed to block estrogen receptors on the surface of breast cancer cells. Estrogen, a growth factor , supports normal breast cell growth by binding to the estrogen receptor (ER) on the cell surface. In breast cancer, these receptors support the growth and proliferation of cancer cells. In most breast cancer types, tumor cells have markedly increased the number of estrogen receptors on their membranes and become dependent on estrogen to grow. These cancers are called hormone-positive breast cancer . Tamoxifen prevents estrogen from binding to its receptor and stops breast cancer cells from growing. It can be used before and after menopause; however, in postmenopausal women, our first choice is other hormone therapies.

Purpose of Treatment

Tamoxifen is most often used after breast cancer surgery to prevent recurrence (adjuvant / preventive treatment). For this purpose, hormone therapy with tamoxifen generally lasts 5-10 years, depending on physician advice. In perimenopausal or postmenopausal patients, after 2-3 years of tamoxifen, an aromatase inhibitor may be used to complete a total of 5-7 years.

Stage 4 disease or inoperable disease is treated to reduce breast cancer-related symptoms, stop cancer spread and extend survival (palliative treatment).

Administration, Dose and Schedule

• Tamoxifen tablets are taken orally, with a starting dose of 20 mg daily.
• Depending on physician advice, it is generally used for 5 -10  years . If hormone therapy is to continue, aromatase inhibitors such as anastrozole or letrozole may be considered afterward.
• If unwanted side effects develop, tamoxifen may be stopped or the regimen changed.

Tamoxifen Side Effects 

Side effects sometimes have percentage ranges [example: hot flashes %38–40]; ranges reflect variation between studies.

• Hot flashes (38–40%)
• Muscle pain (6–21%)
• Night sweats (16%)
• Weakness (15%)
• Mood changes (15%)
• Joint pain (12%)
• Vaginal discharge (11%)
• Nausea and vomiting (10%)
• Vaginal bleeding (7–8%)
• Blood spots on the skin (4%)
• Cataracts (4%)
• Bone fractures (4%)
• Cardiovascular blockages (2–4%)
• Stroke / paralysis (1–2%)
• Endometrial cancer (0.5%)

 Monitoring and Imaging

Monitoring: There is no requirement for specific routine blood tests because of tamoxifen use; investigations are arranged as the physician considers necessary.

Radiological follow-up (early-stage adjuvant): Usually annual mammography + breast ultrasound, whole abdominal ultrasound and chest X-ray; examinations during the first 2 years every 3 months; DEXA every 2 years for postmenopausal patients.

Metastatic/palliative use: Appropriate imaging before treatment and at 2–6-month intervals during treatment to assess response (bone scan, MRI, CT or PET-CT).

Precautions

• If hot flashes affect your life, discuss management options with your doctor. Acupuncture may help some patients. Herbal products may interact with hormone treatments; do not use them without advice from a physician or pharmacist.
• Rarely, venous thromboembolism may develop. Report sudden chest pain, shortness of breath or one-sided leg/arm swelling urgently.
• Because of endometrial thickening and a very small cancer risk, an annual gynecological examination is recommended.
• Drug interactions: certain SSRIs in particular (fluoxetine, paroxetine) may reduce tamoxifen’s effectiveness. Grapefruit interactions may increase blood drug levels; avoid it. Always consult a pharmacist or physician about new medications or supplements.

 Individual Drug Label Information

• Tamoxifen is an oral tablet.
• It is effective in hormone-positive breast cancers, approximately %70 of all breast cancers.
• Risks of a clot in the arm/leg (DVT), a lung clot (PE), heart attack/stroke may increase; a history of clots and smoking raise risk.
• It may be taken with or without food; swallow the tablet whole without crushing.
• If a dose is missed and remembered the same day, take it; if it is the following day, do not double the dose.
• Store at room temperature and protect from light.
• It may interact with antifungals, antidepressants and certain antiepileptics; have your medication list checked.
• Use appropriate birth control; inform your physician if pregnancy occurs.

- You may be interested in: The discovery of tamoxifen, the first targeted drug

 Authorization Status in Turkey

Tamoxifen, in Turkey, for breast cancer that is hormone receptor-positive is used for adjuvant and metastatic/palliative indications, including male breast cancer, and is authorized. It received Turkish authorization on 11.12.1995. Its formulation is generally 10 and 20 mg tablets. Brand names may vary by manufacturer.

• Examples of brand names: Nolvadex, Tadex, Tamoplex, Tamoxifen, Tamoxit, Tamoxifen Cell, etc.
• Price: 10 mg 30 tablets approximately 200 TL, 10 mg 60 tablets 102-244 TL, 10 mg 100 tablets 130-175 TL, 10 mg 250 tablets 75-425 TL, 20 mg 30 tablets 11-243 TL, 20 mg 100 tablets 120-340 TL, 20 mg 250 tablets 810 TL. 

 SGK Reimbursement Status 

Since tamoxifen is standard endocrine therapy for hormone-positive breast cancer, SGK reimbursement coverage is the general rule. The physician’s report specifies the patient’s clinical situation (adjuvant/palliative), report requirements, duration and dose.

• For adjuvant use, it is prescribed with a report from oncology, surgery or the relevant specialty.
• For metastatic use, the indication and previous treatments are specified in the report.
• For rare off-label situations, Medical Board / Off-Label Approval processes may be required.

Practical Suggestions for Tamoxifen Users

• Regular use: Take the drug at the same time every day; if you forget, do not take a double dose.
• Monitoring: Annual gynecological examination (endometrial monitoring), and ophthalmologist assessment for eye symptoms.
• Risk reduction: Quitting smoking, increasing mobility and avoiding prolonged immobilization reduce clot risk.
• Avoiding interactions: In particular, do not use fluoxetine/paroxetine or similar drugs without your physician’s knowledge; do not consume grapefruit .
• Managing side effects: For hot flashes, use lifestyle measures such as layered clothing and reducing caffeine/alcohol; if needed, discuss medication options with your physician.
• Pregnancy/Breastfeeding: Use appropriate birth control; notify your physician immediately of planned or unplanned pregnancy.

XII. References

• NCCN Clinical Practice Guidelines in Oncology — Breast Cancer (current versions).
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta-analyses — Adjuvant endocrine therapy.
• Fisher B, et al. Tamoxifen in the treatment of intraductal breast cancer. NEJM and related classic studies.
• European Society for Medical Oncology (ESMO) Guidelines — ER-positive early and metastatic breast cancer.
• TİTCK — Tamoxifen Summary of Product Characteristics/Package Leaflet (Turkish authorization information).